Platelet-rich plasma for laryngotracheal reconstruction: an experimental study

Önder, Serap Şahin; Yılmaz, Aslı Şahin; Erkmen, Burak; Topal, Cumhur Selçuk; Gergin, Özgül; Canpolat, Mustafa Salih

doi:10.1007/s00405-020-06091-8

Cited by 8 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This trial contributes to further research on PVRP-based treatment for hearing loss ( Stolle et al, 2018 ), facial nerve palsy ( Sánchez et al, 2018 ), dysphonia ( Cobden et al, 2016 ; Özgürsoy et al, 2018 ), dysphagia ( Vidovic and Delling, 2017 ), anosmia ( Yasak et al, 2018 ), soft-tissue defects ( Eryılmaz et al, 2016 ; Tambella et al, 2018 ), or laryngotracheal reconstruction ( Sahin Onder et al, 2020 ). In addition, sterile PVRP could be administered to the sterile human body areas.…”

Section: Discussionmentioning

confidence: 99%

Autologous Platelet- and Extracellular Vesicle-Rich Plasma Is an Effective Treatment Modality for Chronic Postoperative Temporal Bone Cavity Inflammation: Randomized Controlled Clinical Trial

Vozel

Božič

Jeran

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

PurposeTo determine the efficacy of autologous platelet- and extracellular vesicle-rich plasma (PVRP) to treat chronic postoperative temporal bone cavity inflammation (CPTBCI) after exhausting surgical and standard conservative therapies.Materials and MethodsPatients were randomly allocated to treatment with PVRP (PVRP group) or standard conservative methods (control group) in a setting of four once-monthly checkups and subsequent follow-up. The treatment outcome was measured with the Chronic Otitis Media Questionnaire-12 (COMQ-12), CPTBCI focus surface area, and CPTBCI symptom-free time after the fourth checkup.ResultsEleven patients from each group completed the trial; 95% of patients suffered from chronically discharging mastoid cavity (the type of CPTBCI). Within four checkups, the COMQ-12 score decreased statistically significantly in the PVRP group (p < 0.001) but not in the control group (p = 0.339). The CPTBCI foci surface area decreased statistically significantly between the first and second checkups (p < 0.0005) but not between other checkups (p > 0.05) in the PVRP group. No statistically significant differences in CPTBCI foci surface area were detected between checkups in the control group (p = 0.152). Nine patients from the PVRP group and three patients from the control group were CPTBCI symptom-free at the fourth checkup. The median symptom-free time was 9.2 months (95% CI [7.4, 11.9]) in the PVRP group. Cumulatively, 49% of patients in the PVRP group remained CPTBCI symptom-free for 12.7 months after the fourth checkup.ConclusionAutologous PVRP represents a novel additional and successful treatment modality for a chronically discharging radical mastoid cavity when the surgical and standard conservative treatment methods have been exhausted.Trial Numberhttps://clinicaltrials.gov (NCT04281901).

show abstract

Section: Discussionmentioning

confidence: 99%

Autologous Platelet- and Extracellular Vesicle-Rich Plasma Is an Effective Treatment Modality for Chronic Postoperative Temporal Bone Cavity Inflammation: Randomized Controlled Clinical Trial

Vozel

Božič

Jeran

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…With its excellent healing effect on damage, PRP has developed into an attractive therapeutic option with various applications in dermatology [10]. Recently, several studies on airway injuries have reported its healing effect on the airway mucosa [11]. However, PRP faces a natural limitation due to its short shelf life [12].…”

Section: Introductionmentioning

confidence: 99%

“…Platelet-rich plasma (PRP), derived from the concentration of platelet-containing plasma, contains bioactive proteins such as growth factors and peptides known for their regenerative properties [10]. Several studies have demonstrated the therapeutic efficacy of PRP in promoting healing of the airway mucosa after injury [11].…”

Section: Introductionmentioning

confidence: 99%

The Wound Healing of Autologous Regenerative Factor on Recurrent Benign Airway Stenosis: A Canine Experimental and Pilot Study

Chen,

Wang,

et al. 2024

Respiration

View full text Add to dashboard Cite

Introduction: Benign airway stenosis (BAS) is a severe pathologic condition. Complex stenosis has a high recurrence rate and requires repeated bronchoscopic interventions for achieving optimal control, leading to recurrent BAS (RBAS) due to intraluminal granulation. Methods: This study explored the potential of autologous regenerative factor (ARF) for treating RBAS using a post-intubation tracheal stenosis canine model. Bronchoscopic follow-ups were conducted, and RNA-seq analysis of airway tissue was performed. A clinical study was also initiated involving 17 patients with recurrent airway stenosis. Results: In the animal model, ARF demonstrated significant effectiveness in preventing further collapse of the injured airway, maintaining airway patency and promoting tissue regeneration. RNA-seq results showed differential gene expression, signifying alterations in cellular components and signaling pathways. The clinical study found that ARF treatment was well-tolerated by patients with no severe adverse events requiring hospitalization. ARF treatment yielded a high response rate, especially for post-intubation tracheal stenosis and idiopathic tracheal stenosis patients. Conclusion: The study concludes that ARF presents a promising, effective, and less-invasive method for treating RBAS. ARF has shown potential in prolonging the intermittent period and reducing treatment failure in patients with recurrent tracheal stenosis by facilitating tracheal mucosal wound repair and ameliorating tracheal fibrosis. This novel approach could significantly impact future clinical applications.

show abstract

Subglottic and Tracheal Stenosis

Guilcher

Sandu

2022

Textbook of Surgery of Larynx and Trachea

View full text Add to dashboard Cite

Platelet-rich plasma for laryngotracheal reconstruction: an experimental study

Cited by 8 publications

References 27 publications

Autologous Platelet- and Extracellular Vesicle-Rich Plasma Is an Effective Treatment Modality for Chronic Postoperative Temporal Bone Cavity Inflammation: Randomized Controlled Clinical Trial

Autologous Platelet- and Extracellular Vesicle-Rich Plasma Is an Effective Treatment Modality for Chronic Postoperative Temporal Bone Cavity Inflammation: Randomized Controlled Clinical Trial

The Wound Healing of Autologous Regenerative Factor on Recurrent Benign Airway Stenosis: A Canine Experimental and Pilot Study

Subglottic and Tracheal Stenosis

Contact Info

Product

Resources

About